'
Monsenso leads mental health component of H2020 funded WellCo Virtual Coach for Behavioural Changes

Monsenso leads mental health component of H2020 funded WellCo Virtual Coach for Behavioural Changes

Monsenso‘s mHealth solution will lead the mental health component of a new ICT solution designed to help users maintain or improve their physical, cognitive, mental, and social well-being. 

Copenhagen, Denmark – 6 February 2018 Monsenso is proud to be a consortium partner in the international team consisting of SME companies, universities, and research centres for the Horizon 2020 funded WellCo project.

Led by Spanish ICT company Hi-Iberia, the WellCo project will deliver a radically new ICT solution focused on encouraging users to adopt and maintain healthier behavioural choices to help improve their long-term physical, cognitive, mental, and social well-being. The study will mostly be working with older participants.

“WellCo’s aim is to change behaviours and promote a healthy living that will be translated in better quality of life for seniors. One of the main factors is to ensure the acceptance and maintenance of the healthy behaviors promoted by WellCo. The WellCo application will try to make use of the technology as a tool to personalize and tailor these recommendations to the specific needs and preferences of each user.” says Inmaculada Luengo of Hi-Iberia.

The solution will consist of many components, including a comprehensive assessment, personalised advice, and supervised guidance & follow-up for users. WellCo interventions will be guided by an affective aware virtual coach that, through using state of the art technologies in AI (artificial intelligence), will interactively guide and empower users towards important behavioural changes.

Monsenso’s mHealth solution will help contribute experience and knowledge to the project, by providing comprehensive routine monitoring and detailed data collection for assessing the participant’s behaviour.

“We play a leading role in the development of the user assessment and in the design of the virtual coach, and we will also be involved in the prototyping and dissemination components,” says Thomas Lethenborg, CEO of Monsenso. “We are excited to see how we can build on our remote monitoring and sensor data functionality, in order to contribute to collecting longitudinal data to help improve the mental health of participants.”

The virtual coach will be tested in trial in Trento in Italy, Castilla y León in Spain, Copenhagen and the Southern Denmark area in Denmark. There will be a minimum of 150 end-users included in the study. The study will be continuously supported by a multidisciplinary team of experts and users’ close caregivers to ensure the effectiveness and accuracy of the guided wellness interventions.

Other Danish Involvement in the Project 

In Denmark, the University of Copenhagen and The University of Southern Denmark will be working alongside Monsenso in the study.

The University of Copenhagen will contribute to the study with the Quality of Life Lab, which explores the development and evaluation of personal behavioural health metrics by examining how sensor data can be used as a minimally obtrusive method to accurately and longitudinally measure an individual’s behaviour. The lab will also examine how an individual’s quality of life naturally unfolds over time; within this context, the lab will also examine which behavioural change methods can be used to improve the individual’s overall quality of life.

“It is very exciting to be involved in this study and to see how sensor data and remote monitoring can work together to offer a better, more informed, detailed picture of individual’s behaviours for the assessment and improvement of their quality of life and overall well-being.” says Katarzyna Wac, Quality of Life Lab leader and Associate Professor at the University of Copenhagen.

The solution will be implemented, demonstrated, and piloted at The University of Southern Denmark.

“We will be very interested to see how this project effects our elderly patients and their wellbeing, and how much more data and information can be extracted with the use of remote monitoring and sensor data tools,” says Torben Uhrenholt of The University of Southern Denmark.

The Monsenso solution is currently being used in Region South Denmark Clinics.

Consortium Members 

The consortium consists of:

  • 3 SME companies: H-Iberia, a Spanish ICT solution supplying company, Connected Care from The Netherlands and Monsenso
  • Two universities: The University of Copenhagen and The University of Southern Denmark
  • One research center: Jozef Stefan Institute (Slovenia) and two end-user organisations Fondazione Bruno Kessler (Italy) and Gerencia Servicios Sociales Castilla y León (Spain)

The project has launched on December 4th in Madrid and will continue until the end of 2020.

Click here to read the press release in Danish.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No.769765.

About Monsenso: Monsenso is an innovative technology company based in Denmark that offers a comprehensive mHealth solution to optimise the treatment of mental disorders. Our mission is to assist healthcare providers, researchers and individuals in coping with and overcoming the burden of mental illness. Our solution provides a detailed overview of the patient’s mental health through the automatic collection of behavioural data and routine self-monitoring. Our team is committed to developing complete and effective solutions that fit seamlessly within the lives of individuals, in order to increase the quality and efficacy of their treatment.

For additional information, please contact:
Thomas Lethenborg
CEO
Monsenso
+45 30 25 15 26
http://info@monsenso.com

Torben Uhrenholt
IT Project Leader
tuhrenholt@health.sdu.dk

Katarzyna Wac
Quality of Life Lab Leader and Associate Professor at the University of Copenhagen
The University of Copenhagen
wac@di.ku.dk

Using the Monsenso digital self-monitoring tool for borderline treatment

Using the Monsenso digital self-monitoring tool for borderline treatment

The Monsenso digital self-monitoring tool was tested in a pilot study by individuals with Borderline Personality Disorder in a Public-Private Innovation Partnership between The Zealand Healthcare Region and Monsenso.

The Zealand Healthcare Region, which provides medical services to more than 820,000 citizens, was looking for a smartphone-based application to replace the existing paper-based self-assessments and clinical questionnaires. The application was used in a pilot study to support the treatment of 30 patients with Borderline Personality Disorder receiving Dialectical Behavioural Therapy (DBT) and it ran from January 2016 to January 2017.

 Objectives

The main goals of the pilot study were to identify and track the triggers and early warning signs of individuals with BPD using the digital self-monitoring tool, and to evaluate the project from a Mini Medical Technology Assessment (MTV) perspective, in relation to performance, future impact on patient outcomes and financial implications.

Challenges

  • To provide patients and healthcare providers with an effective digital self-monitoring tool that is able to identify and track triggers and early warning signs
  • To optimise the treatment of BPD and to reinforce the recovery process by improving patients’ access to information about their illness
  • To configure, further develop, and install the Monsenso digital self-monitoring tool so that it can be tested in day-to-day operations in the psychiatry unit in Region Zealand

The Monsenso digital self-monitoring tool

The Monsenso mHealth solution is configured to meet the needs and track the symptoms of patients with borderline. It is based on a double-loop treatment model that connects patients and healthcare providers. The Monsenso digital self-monitoring tool gives patients the opportunity to enter and visualise self-reported data and early warning signs. At the same time, the system provides healthcare providers with access to prognosis, statistics, pattern analysis, risk, and tracking of early warning signs. The solution consists of a smartphone application for patients, and a web portal for healthcare providers. The web portal allows care providers to access all the data collected by the patients’ smartphones, and facilitates data analysis. Each clinic has access to an overview of the patients for whom they are responsible. This allows healthcare providers to monitor patients closely in order to quickly identify when the patients’ conditions are changing and document the process patients go through during their treatment.

Results

Since the 30 patients rapidly embraced the app, when the pilot was completed, they had no wish to return to the paper-based self-assessments. Therefore,  The Zealand Healthcare Region chose to extend the agreement with Monsenso for an additional year, even though the project had not been fully evaluated.

The final evaluation, which will be conducted by the Psychiatric Unit of Research of Region Zealand in Slagelse and the Consolidated Unit of Production, Research and Innovation is set to be concluded in early 2017.

The final evaluation includes a round of interviews with patients and staff, who have been testing the Monsenso solution.

Click here to watch a video displaying patient testimonials.

Click on the links below to learn more about Monsenso’s usage in the treatment of Borderline Personality Disorder:

mDiary Study: Designing, implementing, and evaluating a smartphone-based Dialectical Behavioural Therapy

mDiary Study: Designing, implementing, and evaluating a smartphone-based Dialectical Behavioural Therapy

The MDiary Study is a part of the ENTER project (previously called E-Mental), which is being done in collaboration with The Mental Health Services in the Region of Southern Denmark (MHS), the South Denmark University, Aalborg University, and Context Consulting.

Borderline Personality Disorder (BPD)

Borderline is a serious and debilitating mental disorder characterised by difficulties with regulating emotions, which leads to unstable and self-destructive behaviours and relationships.

The prevalence of BPD is 1%-5%. Borderline increases the risk for suicide by 4-fold, while patients with comorbid Borderline and a tendency to self-harm have a further 2-fold attenuated risk. BDP is difficult to treat, and even more difficult when co-occurring with other disorders.

Dialectical Behaviour Therapy (DBT) is the best validated treatment for Borderline, showing medium to large effect sizes as compared to treatment as usual. Dialectical Behaviour Therapy uses self-monitoring as the mainstay of treatment, which helps patients regulate their emotions by means of emotional regulating skills, and reduce problem behaviour.

Self-monitoring has traditionally been done by means of daily paper diaries. The latest developments in smartphone applications have generated alternatives for ecological momentary assessments of problematic behaviour with the additional functionality of prompting patients to practice skills targeting emotion regulation.

Monsenso’s involvement in the the mDIARY Study for patients with Borderline Personality Disorder

Monsenso is responsible for improving and developing additional modules in the Monsenso mHealth solution. The objective of the study is to prove that the Monsenso DBT (Dialectical Behavioural Therapy) solution is a reliable and clinically valid way to collect patient data, helping individuals with Borderline learn these skills at home, speeding up their recovery.

1. Skills tracking
In the current configuration used for DBT treatment, skill used throughout the day can be selected in the daily self-assessment. This does not take into account if the patients have actually learned the skills, meaning a lot of skills will appear in the list that the patient might not already know. In order to personalise the skills list, and in order to help the clinicians and patients to track progress, the skills should be configurable in the sense that the patient is able to indicate whether they have not learned a skill, are in the process of learning a skill, or know it and can use it meaningfully. This implies, the the patients should be able to, on their phone in the configuration section of the self-assessment, to have a list of skills appear, where they can indicate whether a skill is ’Not known’, ’In the process of learning’, or ’I know it, and can use it meaningfully’.

2. Skills training / Psychoeducation
In DBT treatment, skills are an essential part, and patients often have a paper folder, with descriptions of each skill. In the current version, the “Action Plans”’ in the system have been used for this purpose, but it makes it not very easy to overview and need more ways of presenting content, like videos or sound files. The layout is like a dictionary, where patients can find information regarding their disorder, usual treatment regime, prevalence, but alto typical issues and preventive actions that could be taken.

3. Emotion rating (BEARS)
One parameter in the self-assessment should be named “Emotions” in which joy, anger, attachment, sadness, safety, anxiety, pride and shame can be be rated on a scale of 0-4:

0 – Not at all
1 – A Little
2 – Some
3 – A lot
4 – Extreme

It is important that they are all rated in the same screen, as the patient need to see these together.

4. Therapy progress / Detailed overview
The overview screen will be re-designed and focus around “Therapy progress,” highlighting the progress over time. The key factor for the use of the system should be the patients’ development and progress over an extended period. The scope of the solution is to include graphs of the clinical questionnaires in the overview screen, which includes summary scores of DERS, BSL, and HTQ questionnaires. Likewise the attendance percentage should be shown, together with the Hierarchy level rated by the clinician.

To learn more read:

SmartCare by Smartphones – A way towards enhanced patient empowerment: A mixed method study in young adults with schizophrenia

SmartCare by Smartphones – A way towards enhanced patient empowerment: A mixed method study in young adults with schizophrenia

SmartCare by Smartphones was developed in collaboration with the Unit for Psychiatric Research, a group of young patients and their caregivers from the Infirmary for adolescents with schizophrenia in North Jutland.

Schizophrenia

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling and include hallucinations (hearing or seeing things that don’t exist), delusions (unusual beliefs not based on reality), muddled thoughts (based on hallucinations or delusions) and changes in behaviour.

Monsenso’s involvement in SmartCare by Smartphones

The SmartCare by Smartphones project developed a mobile health (mHealth) solution called “MindFrame,”  which is powered by Monsenso, that supports the treatment of individuals with schizophrenia. It consists of a smartphone application for patients and a web portal for clinicians. MindFrame was developed as a framework that offers a unique impression of the correlation between the illness and daily life. Together, healthcare providers and patients can customise the application’s settings so that it corresponds to the person’s actual challenges and supports his particular needs.

MindFrame also provides individuals with customised action plans within the application ensuring that self-help tools are readily available, even when the person is feeling well. Participants are required to fill out a self-assessment on their smartphone; these assessments will reveal the state of the individual’s mental health. The data collected on the self-assessment will be subsequently displayed on the smartphone app as a graph over the course of 14 days.

The clinician can also access the patient’s self-assessments through the clinical web portal enabling him to identify any patterns and make possible connections between certain behaviours and the symptoms they may trigger. With the data from the self-assessments, the system can also identify triggers and early warning signs notifying both, the patient, and the clinician.

To learn more:

MONARCA II Research Project: Monitoring and Predicting Illness Activity in Bipolar Disorder

MONARCA II Research Project: Monitoring and Predicting Illness Activity in Bipolar Disorder

The MONARCA II Research Project aims to establish clinical evidence on the use of the Monsenso system. The MONARCA II trial uses a randomised controlled single-blind parallel-group design.

Mental illness

Approximately 25% of all people in Europe and the US experience a mental illness at least once in their lifetime. Currently, the monitoring of mental illness relies on subjective clinical self-reporting rating scales, which were developed more than 50 years ago. The EU-funded MONARCA project established a platform for the daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones. The system supports the treatment of bipolar disorder by collecting (i) self-rated (‘subjective’) data on parameters like mood, stress, and cognitive problems, and (ii) automatically sensor-based (‘objective’) data the patients behaviour in terms of mobility (GPS), physical activity (accelerometer), social activity (telephony and texting), and general phone usage. This data is captured and forwarded to a server, where it can be accessed, visualised, and monitored by the clinical staff and applied for clinical decision support. The MONARCA system is now further developed and supported by Monsenso.

Monsenso’s involvement in the The MONARCA II RESEARCH PROJECT

Patients with bipolar disorder according to ICD-10 who previously have been treated at the Copenhagen Clinic for Affective Disorder, Denmark are included and randomised to either daily use of the Monsenso system including a feedback loop between patients and clinicians (the intervention group) or to the use of a smartphone for normal communicative purposes (the control group) for a 9-month trial period. The trial started in September 2014.

The outcome measures between the intervention group and the control group are:

  • Differences in depressive and manic symptoms; rate of depressive and manic episodes (primary);
  • Automatically generated objective data on measures of illness activity; number of days hospitalised; psychosocial functioning (secondary);
  • Perceived stress; quality of life; self-rated depressive symptoms; self-rated manic symptoms; recovery; empowerment and adherence to medication (tertiary)
  • Ethical permission has been obtained. Positive, neutral and negative findings will be published.

If the system is effective in reducing depressive and/or manic symptoms (and other symptoms of bipolar disorder) and the rate of episodes, there will be basis for extending the use to the treatment of bipolar disorder in general and in larger scale.

To read more download the research paper:

RADMIS Research Project: A smartphone-based platform that delivers CBT for patients with depression

RADMIS Research Project: A smartphone-based platform that delivers CBT for patients with depression

The RADMIS Research Project is supported by the Innovation Foundation in Denmark and is done in collaboration with the “MONARCA team” with the department of psychiatry represented (RHP) by professor Lars V. Kessing and DTU represented by professors Jakob E. Bardram and Ole Winther.

Depression and bipolar disorder

According to WHO, depression and bipolar disorder are leading causes of disability worldwide, and they cause a high burden in terms of cost, lost productivity, morbidity, suffering, and mortality. According to the European Commission, depression is one of the most pressing public health concerns today, accounting for more than 12% of all estimated ill health and premature mortality in Europe, only exceeded by heart disease and cancer.

Although during the last few decades, psychiatric treatment has shifted more from inpatient treatment to outpatient treatment, the costs of psychiatric hospitalisations are still significant.
In fact, patients with affective disorders are more frequently hospitalised than any other patient group, counting for approximately 20% of all psychiatric hospitalisations.

Monsenso’s involvement in the RADMIS RESEARCH PROJECT

Monsenso is responsible for improving and developing four modules in the Monsenso mHealth solution.

1. Data-collection framework. This task will research and develop a framework for data collection, clustering, preprocessing, and management based on both patient self-reporting and automatic sensor data collection. This will be done as part of the Monsenso platform with input from DTU research on data preprocessing and pathological insight from RHP.

2. Context-aware CBT module. This task will research and develop a module for context-aware (just-in-time) delivery of a rumination-focused CBT and (b) concreteness training, a facilitated self-help intervention intended to increase specificity of processing in patients with depression. This will be done as part of the Monsenso platform with design and technical input from DTU and psychological insight and input from RHP.

3. CBT content. This task will develop multimedia content for CBT training, such as action and coping plans for patients, cartoon and video instruction material, and medication guidance. This content will be developed by psychologist from RHP and incorporated into the CBT module.

4. Illness-forecasting module. This task will research and develop a module for disease forecasting based on research from DTU on correlations analysis and prediction. This module will be included into the Monsenso platform.

To learn more read: